TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03358407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2983559
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2983559
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2983559
Description: GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsules matching GSK2983559 will be available for subjects.
Study: NCT01511367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutiform
Description: 50/5ug (fluticasone/formoterol) 2 puffs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: 50/25 ug (fluticasone/salmeterol) 2 puffs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide
Description: 50ug 2 puffs twice daily
Study: NCT01382875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary management program
Description: conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
Study: NCT03936010

Intervention type: DRUG
Intervention: Canagliflozin
Description: Canagliflozin dispensing claim is exposure

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim is reference
Study: NCT02142790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel liposome injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel liposome injection
Study: NCT01678391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Common bile duct stone removal without fluoroscopy.
Description: ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
Study: NCT01683565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA oil supplement
Description: 2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil Placebo
Description: 2.5mL per day for 90 days
Study: NCT02515331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: Capsule - oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule - oral dose
Study: NCT03565900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study: NCT00687739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: progressive resistance exercise training
Description: 45 minute exercise sessions 4 times per week for 5 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise training
Description: 45 minute exercise sessions 4 times per week for 5 months
Study: NCT00945256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: 45 minuties of treadmill walking was completed at 40% VO2 peak

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: 45 minuties of treadmill walking was completed at 40% VO2 peak

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid Drink
Description: 7.5 gram Amino Acid drink
Study: NCT01828229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: female inactivity and hypercaloric diet
Description: female inactivity and hypercaloric diet for 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inactivity
Description: inactivity for 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inactivity and hypercaloric diet
Description: inactivity and hypercaloric diet for 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal activity and hypercaloric diet
Description: normal activity and hypercaloric diet for 2 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inactivity and iso-caloric diet
Description: inactivity and iso-caloric diet for 2 weeks
Study: NCT03744767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 MG
Description: oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
Study: NCT00186173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school sports program
Description: After school team sports intervention designed specifically for overweight and obese children

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After school health education
Description: After school health and nutrition education program
Study: NCT02926768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-101
Description: Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily
Study: NCT02513901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
Study: NCT04624295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early aspirin Therapy
Description: Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
Study: NCT00820612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100 mg PR once at the time of ERCP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppositories
Description: 2 placebo suppositories at the time of ERCP
Study: NCT00436748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Administered by subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Administered by subcutaneous or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
Study: NCT04624295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-Early aspirin Therapy
Description: Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Study: NCT02600559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Study: NCT04156009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Lavender Elequil aromatabs® (#372)
Description: Activated Lavender aromatherapy tablets wrapped in tape
Study: NCT02033733

Intervention type: DRUG
Intervention: Cisatracurium infusion
Description: This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group).

Intervention type: DRUG
Intervention: Cisatracurium infusion
Description: This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group).
Study: NCT04156009

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unactivated Lavender Elequil aromatabs® (#372)
Description: Unactivated Lavender aromatherapy tablets wrapped in tape
Study: NCT02682966

Intervention type: RADIATION
Intervention: Coronary Computed Tomography Angiography
Description: Coronary Computed Tomography Angiography will be performed in all participants

Intervention type: RADIATION
Intervention: Coronary Computed Tomography Angiography
Description: Coronary Computed Tomography Angiography will be performed in all participants
Study: NCT03156426

Intervention type: OTHER
Intervention: Event of interest: Acute kidney injury
Description: AKI as defined by AKIN staging
Study: NCT03011801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced usual care
Description: Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
Study: NCT03227458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo daily for 36 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: bone-loading exercise on 3 days per week for 38 weeks
Study: NCT02033733

Intervention type: DRUG
Intervention: Cisatracurium prn bolus
Description: Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).

Intervention type: DRUG
Intervention: Cisatracurium prn bolus
Description: Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
Study: NCT02489747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WBE
Description: wheat bran extract (3 g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01610791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, total of 6 infusions
Study: NCT03922568

Intervention type: OTHER
Intervention: Density Gradient Centrifugation
Description: semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume

Intervention type: DEVICE
Intervention: Physiological ICSI
Description: Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection

Intervention type: DEVICE
Intervention: Magnetic Activated Cell Sorting
Description: Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
Study: NCT01971827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-KIDS
Description: MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
Study: NCT00482391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT03227458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: bone-loading exercise on 3 days per week for 38 weeks
Study: NCT00482391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00993785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Costar Coronary Stent Delivery System
Study: NCT02148328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent virosomal influenza vaccine
Description: Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial vaccine 1
Description: Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent virosomal influenza vaccine
Description: Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study: NCT02951182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ
Study: NCT02148328

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial vaccine 2
Description: Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
Study: NCT01069055

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lornoxicam
Description: Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
Study: NCT01664143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Multiple doses of RO5508887
Study: NCT02386111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and sunitinib
Description: During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg.
Study: NCT02951182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Study: NCT01188577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Inhalation Aerosol, HFA
Description: 10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Inhalation Aerosol
Description: Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
Study: NCT02951182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched Placebo
Study: NCT01419834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Description: Hu3F8 is infused IV over \~30 minutes
Study: NCT02800382

Intervention type: OTHER
Group type: OTHER
Intervention: Take samples
Description: Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.

Intervention type: OTHER
Group type: OTHER
Intervention: Take samples
Description: Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
Study: NCT02049008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Photodynamic Therapy
Description: After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
Study: NCT02079493

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Knee replacement
Study: NCT03452722

Intervention type: DRUG
Intervention: intraventricual recombinant tissue plasminogen activator application
Study: NCT03356470

Intervention type: OTHER
Intervention: F-FDG PET/CT
Description: F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
Study: NCT01125449

Intervention type: DRUG
Group type: OTHER
Intervention: Ascorbic acid (vitamin C)
Description: Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.